by Patricia Wilson-Smith | Dec 31, 2025 | Advocacy & Policy, Education, Medicine, Sickle Cell News
In late 2024, Pfizer withdrew voxelotor (Oxbryta) from the market globally after concluding the risks outweighed the benefits. ASH Research Collaborative+1That decision hit patients and clinicians hard—because many people had built their routine around it. New...
